Effects of isoptin and obsidan on the coronary blood flow and tactics in anti-angina therapy of patients with ischemic heart disease
Abstract
Single intravenous doses of isoptin (10 mg) and obsidan (5 mg) were tested for their effects on hemodynamic and coronary blood flow parameters in 35 patients with coronary heart disease and functional classes II-III angina pectoris of effort. In most cases, hemodynamic and coronary blood flow responses to the drug administered were found to be identical. It was concluded that isoptin was effective as an antianginal agent in eukinetic hemodynamics, obsidan, in hyperkinetic one.
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 35 participants or records.
Read the paper
Related studies
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
- Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials
- Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
- Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta‐analysis, and network meta‐analysis of randomized trials with 94,283 participants
- Screen time increases overweight and obesity risk among adolescents: a systematic review and dose-response meta-analysis
- Exposure to WHO AWaRe antibiotics and isolation of multi-drug resistant bacteria: a systematic review and meta-analysis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.